8-K: ImmunityBio Approves Executive Bonuses and Long-Term Incentive Plan, Updates Code of Ethics

ImmunityBio has approved discretionary bonuses for its top executives, established a new long-term incentive program, and updated its code of ethics.

Summary

• ImmunityBio approved discretionary cash bonuses for its named executive officers (NEOs), Dr. Patrick Soon-Shiong, Richard Adcock, and David Sachs, totaling $232,875, $298,500, and $273,980 respectively.
• These bonuses were based on each NEO's performance in 2023 and will be paid around March 15, 2024.
• The company also established a 2024 Long-Term Incentive Program (LTIP) under which NEOs and other employees are eligible for option awards and restricted stock units (RSUs).
• On February 22, 2024, the company granted option awards and RSUs to the NEOs, which will vest ratably over three years.
• Dr. Patrick Soon-Shiong received 342,987 RSUs and options to purchase 1,193,597 shares at an exercise price of $5.24.
• Richard Adcock received 457,317 RSUs and options to purchase 1,591,463 shares at an exercise price of $5.24.
• David Sachs received 121,951 RSUs and options to purchase 424,390 shares at an exercise price of $5.24.
• The company also set the 2024 annual base salaries and target bonuses for the NEOs, effective March 11, 2024.
• Dr. Patrick Soon-Shiong's annual salary is $621,000 with a 75% target bonus, Richard Adcock's is $796,000 with a 75% target bonus, and David Sachs' is $575,358 with a 50% target bonus.
• The Board of Directors approved a new Code of Business Conduct and Ethics, replacing the prior code, to enhance policies including fair dealing and healthcare law compliance.

Sentiment

Score: 7

Explanation: The document reflects standard corporate practices regarding executive compensation and governance, which is generally positive for investors. The long-term incentive plan is a positive sign for future growth.

Positives

• The approval of discretionary bonuses suggests the company is rewarding executive performance.
• The establishment of a long-term incentive program aligns executive interests with long-term company success.
• The vesting schedule of the stock options and RSUs encourages long-term commitment from the executives.
• The updated Code of Ethics demonstrates a commitment to ethical business practices and compliance.

Risks

• The vesting of stock options and RSUs is contingent on continued employment, which could lead to potential executive turnover if not managed well.
• The company's performance will need to support the value of the stock options and RSUs to ensure they are effective incentives.

Future Outlook

The company has established a long-term incentive program to align executive compensation with company performance and long-term growth.

Industry Context

The use of stock options and restricted stock units is a common practice in the biotechnology industry to attract and retain top talent and align their interests with shareholders. The update to the code of ethics is a standard practice for companies as they progress towards commercialization.

Comparison to Industry Standards

• The use of stock options and restricted stock units as part of executive compensation is standard practice in the biotech industry, similar to companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting period of three years for the stock options and RSUs is also typical in the industry, aligning with long-term value creation.
• The target bonus percentages for the NEOs are within the range of what is seen in comparable biotech companies, although specific percentages can vary based on company size and performance.

Corporate Governance

Stakeholder Impact

• Shareholders may view the long-term incentive plan as a positive step towards aligning executive interests with company performance.
• Employees may be motivated by the opportunity to receive stock options and RSUs under the LTIP.
• The updated Code of Ethics may enhance the company's reputation and build trust with stakeholders.

Next Steps

• The 2023 bonuses will be paid on or about March 15, 2024.
• The new annual salaries and target bonuses for NEOs will be effective March 11, 2024.
• The company will continue to implement the 2024 Long-Term Incentive Program.

Key Dates

Keywords

executive compensation, stock options, restricted stock units, long-term incentive plan, code of ethics, corporate governance, bonuses